Cargando…

Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis

Pseudomonas aeruginosa is a bacterial pathogen of global concern and is responsible for 10–15% of nosocomial infections worldwide. This opportunistic bacterial pathogen is known to cause serious complications in immunocompromised patients and is notably the leading cause of morbidity and mortality i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Jordyn A., Rghei, Amira D., Thompson, Brad, Susta, Leonardo, Khursigara, Cezar M., Wootton, Sarah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775905/
https://www.ncbi.nlm.nih.gov/pubmed/36551918
http://dx.doi.org/10.3390/biomedicines10123162
_version_ 1784855748245716992
author Lopes, Jordyn A.
Rghei, Amira D.
Thompson, Brad
Susta, Leonardo
Khursigara, Cezar M.
Wootton, Sarah K.
author_facet Lopes, Jordyn A.
Rghei, Amira D.
Thompson, Brad
Susta, Leonardo
Khursigara, Cezar M.
Wootton, Sarah K.
author_sort Lopes, Jordyn A.
collection PubMed
description Pseudomonas aeruginosa is a bacterial pathogen of global concern and is responsible for 10–15% of nosocomial infections worldwide. This opportunistic bacterial pathogen is known to cause serious complications in immunocompromised patients and is notably the leading cause of morbidity and mortality in patients suffering from cystic fibrosis. Currently, the only line of defense against P. aeruginosa infections is antibiotic treatment. Due to the acquired and adaptive resistance mechanisms of this pathogen, the prevalence of multidrug resistant P. aeruginosa strains has increased, presenting a major problem in healthcare settings. To date, there are no approved licensed vaccines to protect against P. aeruginosa infections, prompting the urgent need alternative treatment options. An alternative to traditional vaccines is vectored immunoprophylaxis (VIP), which utilizes a safe and effective adeno-associated virus (AAV) gene therapy vector to produce sustained levels of therapeutic monoclonal antibodies (mAbs) in vivo from a single intramuscular injection. In this review, we will provide an overview of P. aeruginosa biology and key mechanisms of pathogenesis, discuss current and emerging treatment strategies for P. aeruginosa infections and highlight AAV-VIP as a promising novel therapeutic platform.
format Online
Article
Text
id pubmed-9775905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97759052022-12-23 Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis Lopes, Jordyn A. Rghei, Amira D. Thompson, Brad Susta, Leonardo Khursigara, Cezar M. Wootton, Sarah K. Biomedicines Review Pseudomonas aeruginosa is a bacterial pathogen of global concern and is responsible for 10–15% of nosocomial infections worldwide. This opportunistic bacterial pathogen is known to cause serious complications in immunocompromised patients and is notably the leading cause of morbidity and mortality in patients suffering from cystic fibrosis. Currently, the only line of defense against P. aeruginosa infections is antibiotic treatment. Due to the acquired and adaptive resistance mechanisms of this pathogen, the prevalence of multidrug resistant P. aeruginosa strains has increased, presenting a major problem in healthcare settings. To date, there are no approved licensed vaccines to protect against P. aeruginosa infections, prompting the urgent need alternative treatment options. An alternative to traditional vaccines is vectored immunoprophylaxis (VIP), which utilizes a safe and effective adeno-associated virus (AAV) gene therapy vector to produce sustained levels of therapeutic monoclonal antibodies (mAbs) in vivo from a single intramuscular injection. In this review, we will provide an overview of P. aeruginosa biology and key mechanisms of pathogenesis, discuss current and emerging treatment strategies for P. aeruginosa infections and highlight AAV-VIP as a promising novel therapeutic platform. MDPI 2022-12-07 /pmc/articles/PMC9775905/ /pubmed/36551918 http://dx.doi.org/10.3390/biomedicines10123162 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lopes, Jordyn A.
Rghei, Amira D.
Thompson, Brad
Susta, Leonardo
Khursigara, Cezar M.
Wootton, Sarah K.
Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis
title Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis
title_full Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis
title_fullStr Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis
title_full_unstemmed Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis
title_short Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vectored Immunoprophylaxis
title_sort overcoming barriers to preventing and treating p. aeruginosa infections using aav vectored immunoprophylaxis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775905/
https://www.ncbi.nlm.nih.gov/pubmed/36551918
http://dx.doi.org/10.3390/biomedicines10123162
work_keys_str_mv AT lopesjordyna overcomingbarrierstopreventingandtreatingpaeruginosainfectionsusingaavvectoredimmunoprophylaxis
AT rgheiamirad overcomingbarrierstopreventingandtreatingpaeruginosainfectionsusingaavvectoredimmunoprophylaxis
AT thompsonbrad overcomingbarrierstopreventingandtreatingpaeruginosainfectionsusingaavvectoredimmunoprophylaxis
AT sustaleonardo overcomingbarrierstopreventingandtreatingpaeruginosainfectionsusingaavvectoredimmunoprophylaxis
AT khursigaracezarm overcomingbarrierstopreventingandtreatingpaeruginosainfectionsusingaavvectoredimmunoprophylaxis
AT woottonsarahk overcomingbarrierstopreventingandtreatingpaeruginosainfectionsusingaavvectoredimmunoprophylaxis